Quest Diagnostics Operating Income Over Time
| DGX Stock | USD 202.41 0.03 0.01% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Quest Diagnostics Performance and Quest Diagnostics Correlation. Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Quest Diagnostics. Projected growth potential of Quest fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Quest Diagnostics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.1 | Dividend Share 3.2 | Earnings Share 8.74 | Revenue Per Share | Quarterly Revenue Growth 0.071 |
Investors evaluate Quest Diagnostics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Quest Diagnostics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Quest Diagnostics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Quest Diagnostics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Quest Diagnostics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Quest Diagnostics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Operating Income Analysis
Compare Quest Diagnostics and related stocks such as Carisma Therapeutics, bioAffinity Technologies, and Artelo Biosciences Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CARM | (12.7 M) | (12.7 M) | (19.5 M) | (16.6 M) | (32.9 M) | (35.2 M) | 6.2 M | (20 M) | (25.7 M) | (36.9 M) | (28.4 M) | (28.2 M) | (56.2 M) | (88.7 M) | (62.2 M) | (56 M) | (53.2 M) |
| BIAF | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (2.6 M) | (2.2 M) | (4 M) | (8 M) | (9 M) | (8.1 M) | (7.7 M) |
| ARTL | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.2 K) | (29.7 K) | (232.8 K) | (2.3 M) | (3.2 M) | (4.7 M) | (7.4 M) | (10.3 M) | (9.9 M) | (10.1 M) | (9.1 M) | (8.6 M) |
| REVB | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 10.3 M | 18.8 M | 32.7 M | 38.9 M | (3.6 K) | (145.5 K) | (12 M) | (10.9 M) | (8.7 M) | (8 M) | (7.2 M) | (6.8 M) |
| WOK | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 7.7 M | 1.8 M | 486.5 K | (3.7 M) | (2.5 M) | (2.2 M) | (2.1 M) |
| GTBP | (50 K) | (3.9 M) | (3.5 M) | (793 K) | (2.4 M) | (8.9 M) | (9.4 M) | (135.6 M) | (250.1 M) | (11.5 M) | (6.8 M) | (57.5 M) | (21.3 M) | (13.6 M) | (14.4 M) | (12.9 M) | (13.6 M) |
| PBM | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (334.3 K) | (1.3 M) | (2.8 M) | (3.7 M) | (3.3 M) | (3.1 M) |
| PTIX | (491 K) | (491 K) | (673 K) | (975 K) | (975 K) | (491 K) | (2.2 M) | (2.4 M) | (2.3 M) | (2.1 M) | (2.6 M) | (4.1 M) | (3.6 M) | (4.5 M) | (5.7 M) | (5.1 M) | (5.4 M) |
| AIMD | (800 K) | (1.1 M) | (554.6 K) | (566.2 K) | (622.6 K) | (519.8 K) | (667.1 K) | (579.8 K) | (1.3 M) | (1.6 M) | (1.4 M) | (3.9 M) | (14 M) | (13.2 M) | (13.8 M) | (12.5 M) | (11.8 M) |
| LIPO | (53.8 K) | (53.8 K) | (53.8 K) | (53.8 K) | (53.8 K) | (53.8 K) | (53.8 K) | (53.8 K) | (53.8 K) | (53.8 K) | (56.9 K) | (1.9 M) | (2.6 M) | (4.7 M) | (5.1 M) | (4.6 M) | (4.3 M) |
Quest Diagnostics and related stocks such as Carisma Therapeutics, bioAffinity Technologies, and Artelo Biosciences Operating Income description
Operating Income is the amount of profit realized from Quest Diagnostics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Quest Diagnostics Incorporated is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Quest Diagnostics Incorporated | DGX |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 500 Plaza Drive, |
| Exchange | New York Stock Exchange |
USD 202.41
Additional Tools for Quest Stock Analysis
When running Quest Diagnostics' price analysis, check to measure Quest Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quest Diagnostics is operating at the current time. Most of Quest Diagnostics' value examination focuses on studying past and present price action to predict the probability of Quest Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quest Diagnostics' price. Additionally, you may evaluate how the addition of Quest Diagnostics to your portfolios can decrease your overall portfolio volatility.